

Bibliographie

1. Fattovich, G., Stroffolini, T., Zagni, I. und Donato, F. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology*, **127**, S. S35-50.
2. Herkel, J., Schuchmann, M., Tiegs, G. und Lohse, A.W. (2005) Immune-mediated liver injury. *J Hepatol*, **42**, S. 920-923.
3. Abougergi, M.S., Gidner, S.J., Spady, D.K., Miller, B.C. und Thiele, D.L. (2005) Fas and TNFR1, but not cytolytic granule-dependent mechanisms, mediate clearance of murine liver adenoviral infection. *Hepatology*, **41**, S. 97-105.
4. Sitia, G., Isogawa, M., Iannacone, M., Campbell, I.L., Chisari, F.V. und Guidotti, L.G. (2004) MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. *J Clin Invest*, **113**, S. 1158-1167.
5. Stewart, S.F., Vidali, M., Day, C.P., Albano, E. und Jones, D.E. (2004) Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. *Hepatology*, **39**, S. 197-203.
6. Schumann, J. und Tiegs, G. (1999) Pathophysiological mechanisms of TNF during intoxication with natural or man-made toxins. *Toxicology*, **138**, 103-126.
7. Tilg, H. und Diehl, A.M. (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. *N Engl J Med*, **343**, S. 1467-1476.
8. Tilg, H., Jalan, R., Kaser, A., Davies, N.A., Offner, F.A., Hodges, S.J., Ludwiczek, O., Shawcross, D., Zoller, H., Alisa, A., Mookerjee, R.P., Graziadei, I., Datz, C., Trauner, M., Schuppan, D., Obrist, P., Vogel, W. und Williams, R. (2003) Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. *J Hepatol*, **38**, S. 419-425.
9. Zhang, R., He, X., Liu, W., Lu, M., Hsieh, J.T. und Min, W. (2003) AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. *J Clin Invest*, **111**, S. 1933-1943.
10. Guicciardi, M.E., Deussing, J., Miyoshi, H., Bronk, S.F., Svingen, P.A., Peters, C., Kaufmann, S.H. und Gores, G.J. (2000) Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. *J Clin Invest*, **106**, S. 1127-1137.
11. Gorham, J.D., Lin, J.T., Sung, J.L., Rudner, L.A. und French, M.A. (2001) Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice

- develop necroinflammatory IFN-gamma-dependent hepatitis. *J Immunol*, **166**, S. 6413-6422.
12. Kusters, S., Gantner, F., Kunstle, G. und Tiegs, G. (1996) Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. *Gastroenterology*, **111**, S. 462-471.
 13. Kim, W.H., Hong, F., Radaeva, S., Jaruga, B., Fan, S. und Gao, B. (2003) STAT1 plays an essential role in LPS/D-galactosamine-induced liver apoptosis and injury. *Am J Physiol Gastrointest Liver Physiol*, **285**, S. G761-768.
 14. Doherty, G.M., Lange, J.R., Langstein, H.N., Alexander, H.R., Buresh, C.M. und Norton, J.A. (1992) Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. *J Immunol*, **149**, S. 1666-1670.
 15. Aggarwal, B.B., Eessalu, T.E. und Hass, P.E. (1985) Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. *Nature*, **318**, S. 665-667.
 16. Ruggiero, V., Tavernier, J., Fiers, W. und Baglioni, C. (1986) Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. *J Immunol*, **136**, S. 2445-2450.
 17. McClain, C.J., Cohen, D.A., Dinarello, C.A., Cannon, J.G., Shedlofsky, S.I. und Kaplan, A.M. (1986) Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. *Life Sci*, **39**, S. 1479-1485.
 18. Lin, B.F., Ku, N.O., Zahedi, K., Whitehead, A.S. und Mortensen, R.F. (1990) IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acute-phase reactant mouse serum amyloid P-component (SAP). *Inflammation*, **14**, S. 297-313.
 19. Beg, A.A., Finco, T.S., Nantermet, P.V. und Baldwin, A.S., Jr. (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. *Mol Cell Biol*, **13**, S. 3301-3310.
 20. Streetz, K.L., Tacke, F., Leifeld, L., Wustefeld, T., Graw, A., Klein, C., Kamino, K., Spengler, U., Kreipe, H., Kubicka, S., Muller, W., Manns, M.P. und Trautwein, C. (2003) Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. *Hepatology*, **38**, S. 218-229.
 21. Mizuhara, H., O'Neill, E., Seki, N., Ogawa, T., Kusunoki, C., Otsuka, K., Satoh, S., Niwa, M., Senoh, H. und Fujiwara, H. (1994) T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. *J Exp Med*, **179**, S. 1529-1537.

22. Barton, B.E. und Jackson, J.V. (1993) Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. *Infect Immun*, **61**, S. 1496-1499.
23. Nagaki, M., Tanaka, M., Sugiyama, A., Ohnishi, H. and Moriwaki, H. (1999) Interleukin-10 inhibits hepatic injury und tumor necrosis factor-alpha and interferon-gamma mRNA expression induced by staphylococcal enterotoxin B or lipopolysaccharide in galactosamine-sensitized mice. *J Hepatol*, **31**, S. 815-824.
24. Louis, H., Le Moine, O., Peny, M.O., Quertinmont, E., Fokan, D., Goldman, M. und Deviere, J. (1997) Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. *Hepatology*, **25**, S.1382-1389.
25. Accapezzato, D., Francavilla, V., Paroli, M., Casciaro, M., Chircu, L.V., Cividini, A., Abrignani, S., Mondelli, M.U. und Barnaba, V. (2004) Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. *J Clin Invest*, **113**, S. 963-972.
26. Berg, J.M., Tymoczko, J.L. und Stryer, L. (2003) *Biochemie*. Spektrum Akademischer Verlag GmbH, Heidelberg, Berlin, S. 351-369.
27. Weylandt, K.H. und Kang, J.X. (2005) Rethinking lipid mediators. *Lancet*, **366**, 618-620.
28. Simopoulos, A.P. (2006) Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. *Biomed Pharmacother*, **60**, S. 502-507.
29. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y. und Shimizu, T. (1997) A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. *Nature*, **387**, S. 620-624.
30. Peters-Golden, M., Canetti, C., Mancuso, P. und Coffey, M.J. (2005) Leukotrienes: underappreciated mediators of innate immune responses. *J Immunol*, **174**, S. 589-594.
31. McMahon, B. und Godson, C. (2004) Lipoxins: endogenous regulators of inflammation. *Am J Physiol Renal Physiol*, **286**, S. F189-201.
32. Sinclair, H.M. (1956) Deficiency of essential fatty acids and atherosclerosis, etcetera. *Lancet*, **270**, S. 381-383.
33. Sinclair, H.M. (1981) The relative importance of essential fatty acids of the linoleic und linolenic families: studies with an Eskimo diet. *Prog Lipid Res*, **20**, 897-899.
34. Gil, A. (2002) Polyunsaturated fatty acids und inflammatory diseases. *Biomed Pharmacother*, **56**, S. 388-396.
35. Fischer, S. und Weber, P.C. (1983) Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). *Biochem Biophys Res Commun*, **116**, S. 1091-1099.

36. Lee, T.H., Hoover, R.L., Williams, J.D., Sperling, R.I., Ravalese, J., 3rd, Spur, B.W., Robinson, D.R., Corey, E.J., Lewis, R.A. und Austen, K.F. (1985) Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. *N Engl J Med*, **312**, S. 1217-1224.
37. Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J.A. und Reddy, S.T. (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. *Proc Natl Acad Sci U S A*, **100**, S. 1751-1756.
38. James, M.J., Cleland, L.G., Gibson, R.A. und Hawkes, J.S. (1991) Interaction between fish and vegetable oils in relation to rat leucocyte leukotriene production. *J Nutr*, **121**, S. 631-637.
39. Babcock, T.A., Novak, T., Ong, E., Jho, D.H., Helton, W.S. und Espat, N.J. (2002) Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor-alpha production by omega-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. *J Surg Res*, **107**, S. 135-139.
40. Mayer, K., Meyer, S., Reinholz-Muhly, M., Maus, U., Merfels, M., Lohmeyer, J., Grimminger, F. und Seeger, W. (2003) Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. *J Immunol*, **171**, 4837-4843.
41. Endres, S., Ghorbani, R., Kelley, V.E., Georgilis, K., Lonnemann, G., van der Meer, J.W., Cannon, J.G., Rogers, T.S., Klempner, M.S., Weber, P.C. und et al. (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med*, **320**, S. 265-271.
42. Novak, T.E., Babcock, T.A., Jho, D.H., Helton, W.S. und Espat, N.J. (2003) NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. *Am J Physiol Lung Cell Mol Physiol*, **284**, S. L84-89.
43. Belluzzi, A., Boschi, S., Brignola, C., Munarini, A., Cariani, G. und Miglio, F. (2000) Polyunsaturated fatty acids and inflammatory bowel disease. *Am J Clin Nutr*, **71**, S. 339S-342S.
44. (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet*, **354**, S. 447-455.

45. Kremer, J.M. (2000) n-3 fatty acid supplements in rheumatoid arthritis. *Am J Clin Nutr*, **71**, S. 349S-351S.
46. Hudert, C.A., Weylandt, K.H., Lu, Y., Wang, J., Hong, S., Dignass, A., Serhan, C.N. und Kang, J.X. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. *Proc Natl Acad Sci U S A*, **103**, S. 11276-11281.
47. Serhan, C.N., Arita, M., Hong, S. und Gotlinger, K. (2004) Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. *Lipids*, **39**, S. 1125-1132.
48. Hong, S., Gronert, K., Devchand, P.R., Moussignac, R.L. und Serhan, C.N. (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. *J Biol Chem*, **278**, S. 14677-14687.
49. Serhan, C.N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S.P. und Petasis, N.A. (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. *J Immunol*, **176**, S. 1848-1859.
50. Okano, J., Shiota, G. und Kawasaki, H. (1997) Protective action of hepatocyte growth factor for acute liver injury caused by D-galactosamine in transgenic mice. *Hepatology*, **26**, S. 1241-1249.
51. Sinclair, S.B. und Levy, G.A. (1991) Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report. *Dig Dis Sci*, **36**, 791-800.
52. Tiegs, G. und Wendel, A. (1988) Leukotriene-mediated liver injury. *Biochem Pharmacol*, **37**, S. 2569-2573.
53. Watanabe, S. und Okuyama, H. (1991) Effect of dietary alpha-linolenate/linoleate balance on endotoxin-induced hepatitis in mice. *Lipids*, **26**, 467-471.
54. Kang, J.X., Wang, J., Wu, L. und Kang, Z.B. (2004) Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. *Nature*, **427**, S. 504.
55. Sass, G., Heinlein, S., Agli, A., Bang, R., Schumann, J. und Tiegs, G. (2002) Cytokine expression in three mouse models of experimental hepatitis. *Cytokine*, **19**, S. 115-120.
56. Decker, K. und Keppler, D. (1974) Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. *Rev Physiol Biochem Pharmacol*, S. 77-106.

57. Freudenberg, M.A., Keppler, D. und Galanos, C. (1986) Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. *Infect Immun*, **51**, S. 891-895.
58. Lehmann, V., Freudenberg, M.A. und Galanos, C. (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. *J Exp Med*, **165**, S. 657-663.
59. Josephs, M.D., Bahjat, F.R., Fukuzuka, K., Ksontini, R., Solorzano, C.C., Edwards, C.K., 3rd, Tannahill, C.L., MacKay, S.L., Copeland, E.M., 3rd und Moldawer, L.L. (2000) Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand. *Am J Physiol Regul Integr Comp Physiol*, **278**, S. R1196-1201.
60. Luster, M.I., Germolec, D.R., Yoshida, T., Kayama, F. und Thompson, M. (1994) Endotoxin-induced cytokine gene expression and excretion in the liver. *Hepatology*, **19**, S. 480-488.
61. Chensue, S.W., Terebuh, P.D., Remick, D.G., Scales, W.E. und Kunkel, S.L. (1991) In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. *Am J Pathol*, **138**, S. 395-402.
62. Kang, J.X. und Wang, J. (2005) A simplified method for analysis of polyunsaturated fatty acids. *BMC Biochem*, **6**, S. 5.
63. Reitman, S. und Frankel, S. (1957) A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol*, **28**, S. 56-63.
64. Bradford, M.M. (1976) A rapid und sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*, **72**, S. 248-254.
65. Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R.N. und et al. (1995) Histological grading and staging of chronic hepatitis. *J Hepatol*, **22**, S. 696-699.
66. Knodell, R.G., Ishak, K.G., Black, W.C., Chen, T.S., Craig, R., Kaplowitz, N., Kiernan, T.W. und Wollman, J. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology*, **1**, S. 431-435.

67. Babcock, T.A., Helton, W.S., Hong, D. und Espat, N.J. (2002) Omega-3 fatty acid lipid emulsion reduces LPS-stimulated macrophage TNF-alpha production. *Surg Infect (Larchmt)*, **3**, S. 145-149.
68. Nanji, A.A., Jokelainen, K., Lau, G.K., Rahemtulla, A., Tipoe, G.L., Polavarapu, R. und Lalani, E.N. (2001) Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration. *J Pharmacol Exp Ther*, **299**, S. 832-839.
69. Nanji, A.A., Zhao, S., Sadrzadeh, S.M., Dannenberg, A.J., Tahan, S.R. und Waxman, D.J. (1994) Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats. *Alcohol Clin Exp Res*, **18**, S. 1280-1285.
70. Gonzalez-Periz, A., Planaguma, A., Gronert, K., Miquel, R., Lopez-Parra, M., Titos, E., Horrillo, R., Ferre, N., Deulofeu, R., Arroyo, V., Rodes, J. und Claria, J. (2006) Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. *Faseb J*, **20**, S. 2537-2539.
71. Scaffidi, P., Misteli, T. und Bianchi, M.E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*, **418**, S. 191-195.
72. Leist, M., Gantner, F., Jilg, S. und Wendel, A. (1995) Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. *J Immunol*, **154**, S. 1307-1316.
73. Tapalaga, D., Tiegs, G. und Angermuller, S. (2002) NFkappaB and caspase-3 activity in apoptotic hepatocytes of galactosamine-sensitized mice treated with TNFalpha. *J Histochem Cytochem*, **50**, S. 1599-1609.
74. Yamada, Y., Kirillova, I., Peschon, J.J. und Fausto, N. (1997) Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. *Proc Natl Acad Sci U S A*, **94**, S. 1441-1446.
75. Simopoulos, A.P. (1996) The role of fatty acids in gene expression: health implications. *Ann Nutr Metab*, **40**, S. 303-311.
76. Fritsche, K.L., Byrge, M. und Feng, C. (1999) Dietary omega-3 polyunsaturated fatty acids from fish oil reduce interleukin-12 and interferon-gamma production in mice. *Immunol Lett*, **65**, S. 167-173.
77. James, M.J., Gibson, R.A. und Cleland, L.G. (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. *Am J Clin Nutr*, **71**, S. 343S-348S.

78. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A. und Serhan, C.N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med*, **201**, S. 713-722.
79. Walker, W., Aste-Amezaga, M., Kastelein, R.A., Trinchieri, G. und Hunter, C.A. (1999) IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. *J Immunol*, **162**, S. 5894-5901.
80. Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K. und et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. *Nature*, **378**, S. 88-91.
81. Kontogianna, M., Gupta, A., Ntanios, F., Graham, T., Jones, P. und Meterissian, S. (2000) omega-3 fatty acids decrease endothelial adhesion of human colorectal carcinoma cells. *J Surg Res*, **92**, S. 201-205.
82. El-Badry, A.M., Moritz, W., Contaldo, C., Tian, Y., Graf, R. und Clavien, P.A. (2007) Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. *Hepatology*, **45**, S. 855-863.
83. Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N. und Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med*, **192**, S. 1197-1204.
84. Cabre, E. und Gassull, M.A. (1999) Feeding long-chain PUFA to advanced cirrhotics: is it worthwhile? *Nutrition*, **15**, S. 322-324.
85. Watanabe, A., Saito, S., Tsuchida, T., Higuchi, K. und Okita, M. (1999) Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. *Nutrition*, **15**, S. 284-288.
86. Cabre, E. und Gassull, M.A. (1996) Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. *Nutrition*, **12**, 542-548.
87. Balkwill, F. und Mantovani, A. (2001) Inflammation and cancer: back to Virchow? *Lancet*, **357**, S. 539-545.
88. Karin, M., Cao, Y., Greten, F.R. und Li, Z.W. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer*, **2**, S. 301-310.
89. Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E. und Ben-Neriah, Y. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature*, **431**, S. 461-466.

90. Beharry, S., Ackerley, C., Corey, M., Kent, G., Heng, Y.M., Christensen, H., Luk, C., Yantiss, R.K., Nasser, I.A., Zaman, M., Freedman, S.D. und Durie, P.R. (2007) Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. *Am J Physiol Gastrointest Liver Physiol*, **292**, S. G839-848.